Vividion Therapeutics, Inc. San Diego, CA 92121 Attn: Chief Executive Officer Re: Addition of Stat3 to Master Research and Collaboration Agreement Dear Sir or Madam:
Exhibit 10.13
September 20, 2019
Via Email and FedEx
0000 Xxxxxxx Xxxxxxx Xx., Xxxxx 000
Xxx Xxxxx, XX 00000
Attn: Chief Executive Officer
Re: Addition of Stat3 to Master Research and Collaboration Agreement
Dear Sir or Madam:
This letter agreement (the “Letter Agreement”) is being entered into by and between Vividion Therapeutics, Inc. (“Vividion”) and Celgene Corporation (“Celgene”), in connection with the Master Research and Collaboration Agreement entered into by Vividion and Celgene dated March 1, 2018 (the “Collaboration Agreement”), pursuant to which Celgene and Vividion agreed to collaborate on the research and development of therapeutics directed against certain targets. Capitalized terms used in this Letter Agreement that are not otherwise defined herein have the meanings set forth in the Collaboration Agreement.
The Parties hereby acknowledge and agree, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, as follows:
1. Stat3 is hereby added to the Collaboration as a Deal Target, and Schedule 1.1.35 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the revised Schedule 1.1.35 attached hereto as Exhibit A.
“First Program” as defined in the Collaboration Agreement and shall be a Licensed Program; (ii) if the Stat3 Deal Target Program is the first Deal Target Program or E3 Ligase Program for which Celgene exercises its Opt-In Right after the First Program, the Stat3 Deal Target Program shall be designated as both a Shared Global Program and a Vividion Lead Shared Program, and, per Section 3.1.1 (b)(i) of the Collaboration Agreement, the next subsequent Deal Target Program or E3 Ligase Program for which Celgene exercises its Opt-In Right shall be a Shared US Program; and (iii) if the Stat 3 Deal Target Program is the second Deal Target Program or E3 Ligase Program for which Celgene exercises its Opt-In Right after the First Program, the Stat3 Deal Target Program shall be designated as both a Shared Global Program and a Vividion Lead Shared Program, and, per Section 3.1.1(b)(ii) of the Collaboration Agreement, the next subsequent Deal Target Program or E3 Ligase Program for which Celgene exercises its Opt-In Right shall also be a Shared Global Program and a Vividion Lead Shared Program.
3. This Letter Agreement shall be deemed incorporated into and made a part of the Collaboration Agreement. The provisions of this Letter Agreement shall constitute an amendment to the Collaboration Agreement, and, to the extent that any term or provision of this Letter Agreement is inconsistent with any term or provision in the Collaboration Agreement, this Letter Agreement shall govern and control. Except as expressly amended by this Letter Agreement, all other terms and conditions of the Collaboration Agreement shall remain unchanged, and the Collaboration Agreement shall remain in full force and effect as presently written, and the rights, duties, liabilities and obligations of Celgene and Vividion thereto, as presently constituted, will continue in full effect.
4. By his or her execution of this Letter Agreement, each of the signatories below represents and warrants, on behalf of himself or herself and on behalf of the Party on whose behalf he or she is signing, that (a) he or she is a duly authorized representative of the Party on whose behalf he or she is signing, (b) he or she is duly authorized by such Party to execute this Letter Agreement on behalf of such Party and (c) this Letter Agreement has been duly executed and delivered on behalf of such Party and is a legal and valid obligation binding upon such Party and is enforceable in accordance with its terms.
5. This Letter Agreement may be executed in two (2) counterparts, each of which shall be deemed an original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of Electronic Delivery shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or defense with respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity.
[Signature pages follow]
| Very truly yours | ||
| CELGENE CORPORATION | ||
| By: |
/s/ Xxxxxx Xxxxxx | |
| Name: |
Xxxxxx Xxxxxx | |
| Title: |
Exec. VP & President | |
| Global Research & Early Dev. | ||
Agreed and accepted as of the date set forth above:
| By: |
/s/ G. Xxxxx Xxxxxxxx | |
| Name: |
G. Xxxxx Xxxxxxxx | |
| Title: |
Chief Executive Officer | |
| Cc: |
0000 Xxxxxxx Xxxxxxx Xx., Xxxxx 000
Xxx Xxxxx, XX 00000
Attn: Legal Department
and
WilmerHale
00 Xxxxx Xxxxxx
Xxxxxx, XX 00000
Attn: Xxxxxx X. Xxxxxx and Xxxxxx X. Xxxxxxx
Exhibit A
SCHEDULE 1.1.35
DEAL TARGETS